Recent developments among world’s leading generic markets
Sažetak
Possible net savings achievable via generic substitution of brand name drugs could reach even € 30 billion within EU’s disposable health care expenditure. Seemingly this trend could could be recognized in world major national pharmaceutical markets, the US and Japan, as well as among major emerging economies such as Brasil, Russia, India and China. Different policy strategies in order to stimulate generic medicines prescription, dispensing and sales have been deployed in these countries over the course of past three decades with variable success rates. This contribution should provide short overview of current trends in these pharmaceutical markets.
Reference
Shepard A. Principal, Global Generics, Thought Leadership. IMS Health, Generic Medicines: Essential contributors to the long-term health of society. Sector Sustainability Challenges in Europe, Brussels March 25th 2010.
(http://www.imshealth.com/imshealth/Global/Content/IMS%20Institute/Documents/Generics_Medicines.pdf)
Danzon PM, Furukawa MF. Prices and availability of biopharmaceuticals: an international comparison. Health Aff (Millwood) 2006; 25(5): 1353-62.
Decollogny A, Eggli Y, Halfon P, Lufkin TM. Determinants of generic drug substitution in Switzerland. BMC Health Serv Res 2011; 11: 17
Yamada T, Chen CC, Yamada T, Chiu IM, and Worrall J. Pharmaceutical Price Control Policy, Pharmaceutical Innovation, and Health Durability. The Open Pharmacoeconomics & Health Economics Journal 2010; 2: 34-46.
Sachiko M. The Market Exclusivity Period for New Drugs in Japan: Overview of Intellectual Property Protection and Related Regulations. Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector 2008; 5(2): 121-130.
Berndt ER, Mortimer R, Bhattacharjya A, Parece A, Tuttle E. Authorized generic drugs, price competition, and consumers' welfare. Health Aff (Millwood) 2007; 26(3): 790-9.
Frank RG. The ongoing regulation of generic drugs. N Engl J Med 2007; 357(20): 1993-6.
Peters JR, Hixon DR, Conner DP, Davit BM, Catterson DM, Parise CM. Generic drugs--safe, effective, and affordable. Dermatol Ther 2009; 22(3): 229-40.
Danzon MP, Furukawa FM. Cross-National Evidence on Generic Pharmaceuticals: Pharmacy vs. Physician-Driven Markets. NBER Working Paper 2011; 17226.
Jakovljevic MB, Nakazono S, Ogura S. Contemporary generic market in Japan - key conditions to successful evolution. Expert Rev Pharmacoecon Outcomes Res.2014 Jan 23.DOI:10.1586/14737167.2014.881254.
Babar ZU, Grover P, Stewart J, et al. Evaluating pharmacists' views, knowledge, and perception regarding generic medicines in New Zealand. Res Social Adm Pharm. 2011; 7(3): 294-305.
Lofgren H. Generic drugs: international trends and policy developments in Australia. Aust Health Rev 2004; 27(1): 39-48.
Searles A, Jefferys S, Doran E, Henry DA. Reference pricing, generic drugs and proposed changes to the Pharmaceutical Benefits Scheme. Med J Aust 2007; 187(4): 236-9.
Liu YM, Yang YH, Hsieh CR. Financial incentives and physicians' prescription decisions on the choice between brand-name and generic drugs: evidence from Taiwan. J Health Econ 2009; 28(2): 341-9.
Shukla N, Sangal T. Generic Drug Industry in India: The Counterfeit Spin, Journal of Intellectual Property Rights JIPR 2009; 14(3): 236-240.
Sun Q, Santoro MA, Meng Q, Liu C, Eggleston K. Pharmaceutical policy in China. Health Aff (Millwood) 2008; 27(4): 1042-50.